Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1927–1930. doi: 10.1128/aac.37.9.1927

Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.

P H Chandrasekar 1, J A Sluchak 1, J A Kruse 1
PMCID: PMC188094  PMID: 8239607

Abstract

Using a granulocytopenic murine model, we evaluated the efficacy of cefoperazone plus sulbactam against disseminated infection due to isolates of beta-lactamase-producing, cefoperazone-resistant (MIC, > or = 50 micrograms/ml) Escherichia coli and Pseudomonas aeruginosa. Both isolates were susceptible in vitro to cefoperazone plus sulbactam (MIC, < or = 6.3 micrograms/ml). Mice rendered granulocytopenic with cyclophosphamide were divided into three groups: group A--infected, untreated mice (controls); group B--infected, cefoperazone-treated mice (700 mg/kg of body weight); and group C--infected, cefoperazone-plus-sulbactam-treated mice (700 mg plus 350 mg). In the E. coli experiment, survival rates in groups A, B, and C were 25, 46, and 73%, respectively. In the experiment with P. aeruginosa, survival rates in groups A, B, and C were 0, 10, and 50%, respectively (P < 0.001). Highly significant differences also were noted for colony counts in the blood, liver, and spleen of group C mice versus group A or B mice in both experiments. Thus, cefoperazone plus sulbactam appears to be a promising combination for the treatment of infections due to certain cefoperazone-resistant gram-negative bacilli, including P. aeruginosa.

Full text

PDF
1927

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Miller P., Ho D. H. In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):209S–214S. doi: 10.1016/0732-8893(89)90138-7. [DOI] [PubMed] [Google Scholar]
  2. Chandrasekar P. H., Sluchak J. A. In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone. Infection. 1991 Jan-Feb;19(1):49–53. doi: 10.1007/BF01643761. [DOI] [PubMed] [Google Scholar]
  3. Cryz S. J., Jr, Fürer E., Germanier R. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun. 1983 Mar;39(3):1067–1071. doi: 10.1128/iai.39.3.1067-1071.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gerber A. U., Kozak S., Segessenmann C., Flückiger U., Bangerter T., Greter U. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):233–237. doi: 10.1007/BF01965266. [DOI] [PubMed] [Google Scholar]
  5. Horiuchi A., Hasegawa H., Kageyama T., Yonezawa T., Kitani T., Masaoka T., Yasunaga K., Kawagoe H., Nagai K. Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):215S–219S. doi: 10.1016/0732-8893(89)90139-9. [DOI] [PubMed] [Google Scholar]
  6. Jacobs M. R., Aronoff S. C., Johenning S., Shlaes D. M., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1986 Jun;29(6):980–985. doi: 10.1128/aac.29.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jauregui L. E., Appelbaum P. C., Fabian T. C., Hageage G., Strausbaugh L., Martin L. F. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1990 Mar;25(3):423–433. doi: 10.1093/jac/25.3.423. [DOI] [PubMed] [Google Scholar]
  8. Jones R. N., Wilson H. W., Thornsberry C., Barry A. L. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn Microbiol Infect Dis. 1985 Nov;3(6):489–499. doi: 10.1016/s0732-8893(85)80005-5. [DOI] [PubMed] [Google Scholar]
  9. Klastersky J., Van der Auwera P. In vitro activity of sulbactam in combination with various beta-lactam antibiotics. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):165S–169S. doi: 10.1016/0732-8893(89)90130-2. [DOI] [PubMed] [Google Scholar]
  10. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  11. Santos J. I., Arbo A. The in vitro effect of sulbactam on polymorphonuclear leukocyte function. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):147S–152S. doi: 10.1016/0732-8893(89)90127-2. [DOI] [PubMed] [Google Scholar]
  12. Winston D. J., Ho W. G., Bruckner D. A., Champlin R. E. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991 Dec 1;115(11):849–859. doi: 10.7326/0003-4819-115-11-849. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES